Array Biopharma and Pfizer have struck a clinical trial collaboration to study several cancer-targeting combos, which will include the former's MEK inhibitor and a PARP inhibitor and anti PD-L1 med ...

BARCELONA—Positive new colorectal cancer data has Pfizer envisioning a launch for its newly acquired Array BioPharma meds. And the company is getting prepared. Monday at the European Society for ...

Boulder-based biopharmaceutical company Array BioPharma (Nasdaq: ARRY) reported Monday that it had presented clinical trial results on the combination of two of its cancer-fighting drugs at the ...

Using customized DNA arrays to assess the activity of 4,500 different genes in a leukemic form of lymphoma known as Sezary syndrome, researchers at The Wistar Institute have identified 385 genes that ...

Boulder-based pharmaceutical firm Array BioPharma Inc. has received the U.S. Food and Drug Administration’s breakthrough therapy designation for an investigational drug combination to treat colorectal ...

Oncothyreon will join Array BioPharma in developing its early clinical-stage small molecule HER2 inhibitor ARRY-380 by agreeing to fund proof-of-concept trials in patients with metastatic breast ...

Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, will launch its new CytoSure™ Consortium Cancer +SNP array (4x180k) at the ...

Immunotherapies have already shown startling effectiveness against certain previously intractable cancers and a pair of scientists were awarded this year’s Nobel Prize for their research into immune ...

Pfizer will purchase Array BioPharma for $10.4 billion. It hopes to expand its cancer portfolio with targeted therapies. This acquisition underscores the importance of cancer drugs to the ...